US FDA Slams Zydus For Flawed Investigation, ‘Unofficial’ Books
This article was originally published in PharmAsia News
Executive Summary
A US FDA warning letter against Zydus Cadila's Indian sites contains some sharp references to the firm's flawed investigations into warfarin tablet failures, controls over computerized systems and poor documentation practices.